Study: Abortion Pill Complications Far Exceed FDA Claims

A large-scale study by the Ethics and Public Policy Center (EPPC) analyzed insurance claims from 865,727 mifepristone prescriptions between 2017 and 2023, finding a 10.93% rate of serious adverse events, including sepsis, hemorrhaging, infection, or emergency surgery, within 45 days of use. This rate is at least 22 times higher than the less than 0.5% complication rate listed on the FDA-approved drug label, which is based on smaller, older trials. The study's authors and several medical professionals are urging the FDA to reinstate stricter safety protocols and reconsider mifepristone’s approval, arguing that these new findings challenge the prevailing safety narrative promoted by abortion-rights advocates, the FDA, and Danco Laboratories, the drug’s manufacturer. Critics have pointed out the study's sponsorship by a conservative think tank and are calling for independent research to validate the results. The FDA and Danco Laboratories have not yet responded to the study. The findings are intensifying calls for regulatory review and greater transparency regarding medication abortion risks.